ConductScience.org, home
Papers
API referenceFor AI assistants

Paper · 40526877

Functional Characterization of Variants of Unknown Significance of Fibroblast Growth Factor Receptors 1-4 and Comparison With AI Model-Based Prediction.

Ziegler M and 4 others. JCO Precis Oncol, 2025. Cited by 2 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Functional Characterization of Variants of Unknown Significance of Fibroblast Growth Factor Receptors 1-4 and Comparison With AI Model-Based Prediction. Papers, record 40526877. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40526877

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Functional Characterization of Variants of Unknown Significance of Fibroblast Growth Factor Receptors 1-4 and Comparison With AI Model-Based Prediction.
PubMed
Journal
JCO Precis Oncol
PubMed
Year
2025
PubMed
Publication types
Journal Article, Comparative Study
PubMed
Citations, by iCite
2
iCite
Revised in PubMed
2025-06-25
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Ziegler MMartinhttps://orcid.org/0000-0003-2137-5234
2Khoury NNadira
3Hommerich LMLouisa Maxinehttps://orcid.org/0009-0006-1615-8613
4Adler HHeike
5Loges SSonjahttps://orcid.org/0000-0002-7650-8527

Source PubMed

Topics5

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Artificial IntelligenceMajor topic
NeoplasmsMajor topic
Receptors, Fibroblast Growth FactorMajor topic
Humans
Mutation

Source PubMed

Grants0

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

None in this release.

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References60

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
18,755,573Constitutive receptor activation by Crouzon syndrome mutations in fibroblast growth factor receptor (FGFR)2 and FGFR2/Neu chimeras.Proc Natl Acad Sci U S A1996https://conductscience.org/library/papers/8755573PubMed
228,615,371A Phase Ib Open-Label Multicenter Study of AZD4547 in Patients with Advanced Squamous Cell Lung Cancers.Clin Cancer Res2017https://conductscience.org/library/papers/28615371PubMed
330,686,944plotROC: A Tool for Plotting ROC Curves.J Stat Softw2017https://conductscience.org/library/papers/30686944PubMed
429,533,785Systematic Functional Annotation of Somatic Mutations in Cancer.Cancer Cell2018https://conductscience.org/library/papers/29533785PubMed
532,463,741Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W.J Clin Oncol2020https://conductscience.org/library/papers/32463741PubMed
69,136,983Activation of FGF receptors by mutations in the transmembrane domain.Oncogene1997https://conductscience.org/library/papers/9136983PubMed
734,463,891A pilot study of Pan-FGFR inhibitor ponatinib in patients with FGFR-altered advanced cholangiocarcinoma.Invest New Drugs2022https://conductscience.org/library/papers/34463891PubMed
836,026,442Cancer-driving mutations are enriched in genic regions intolerant to germline variation.Sci Adv2022https://conductscience.org/library/papers/36026442PubMed
930,371,878COSMIC: the Catalogue Of Somatic Mutations In Cancer.Nucleic Acids Res2019https://conductscience.org/library/papers/30371878PubMed
10560,061Primary bioassay of human tumor stem cells.Science1977https://conductscience.org/library/papers/560061PubMed

1 to 10 of 60

See all 60 references

Cited by1

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.

PMIDTitleJournalYearIn Papers
41,678,281Mutated FGFR1 is an oncogenic driver and therapeutic target in high-risk neuroblastoma.J Clin Invest2026https://conductscience.org/library/papers/41678281

Source PubMed

Genes4

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
FGFR12,260PubTator's text mininghttps://conductscience.org/library/genes/2260NCBI Gene
FGFR22,263PubTator's text mininghttps://conductscience.org/library/genes/2263NCBI Gene
FGFR32,261PubTator's text mininghttps://conductscience.org/library/genes/2261NCBI Gene
FGFR42,264PubTator's text mininghttps://conductscience.org/library/genes/2264NCBI Gene

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/40526877

GET https://conductscience.org/api/papers/v1/40526877/references?page=2

API referenceFor AI assistants